A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)

Trial Profile

A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Lintuzumab Ac-225 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 12 Feb 2018 According to an Actinium Pharmaceuticals media release, the company expects report top line data in the second half of 2018.
    • 06 Feb 2018 According to an Actinium Pharmaceuticals media release, the company expects to complete enrollment in the second half of 2018.
    • 13 Sep 2017 According to an Actinium Pharmaceuticals media release, updates from the study will be presented at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top